ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $4,495,143 | -10.8% | 282,181 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $5,037,000 | +0.1% | 282,181 | -0.1% | 0.00% | 0.0% |
| Q2 2022 | $5,032,000 | +293.4% | 282,374 | +283.9% | 0.00% | +100.0% |
| Q3 2021 | $1,279,000 | -38.3% | 73,552 | -10.2% | 0.00% | 0.0% |
| Q2 2021 | $2,073,000 | +50.8% | 81,947 | +23.2% | 0.00% | 0.0% |
| Q1 2021 | $1,375,000 | -48.2% | 66,517 | +36.4% | 0.00% | -50.0% |
| Q4 2020 | $2,653,000 | +2.5% | 48,752 | -21.5% | 0.00% | 0.0% |
| Q3 2020 | $2,589,000 | -39.7% | 62,116 | -18.9% | 0.00% | -50.0% |
| Q2 2020 | $4,295,000 | +21.3% | 76,594 | -9.9% | 0.00% | 0.0% |
| Q1 2020 | $3,542,000 | -16.5% | 84,974 | -14.3% | 0.00% | +33.3% |
| Q4 2019 | $4,240,000 | +107.8% | 99,110 | +74.9% | 0.00% | +50.0% |
| Q3 2019 | $2,040,000 | +32.5% | 56,680 | -1.6% | 0.00% | +100.0% |
| Q2 2019 | $1,540,000 | +8.1% | 57,617 | +8.6% | 0.00% | 0.0% |
| Q1 2019 | $1,424,000 | +547.3% | 53,038 | +289.9% | 0.00% | – |
| Q4 2018 | $220,000 | +746.2% | 13,603 | +1002.4% | 0.00% | – |
| Q3 2018 | $26,000 | -38.1% | 1,234 | -55.3% | 0.00% | – |
| Q2 2018 | $42,000 | -82.9% | 2,763 | -74.8% | 0.00% | – |
| Q1 2018 | $246,000 | -65.7% | 10,959 | -54.0% | 0.00% | -100.0% |
| Q4 2017 | $717,000 | +5875.0% | 23,826 | +7186.2% | 0.00% | – |
| Q3 2017 | $12,000 | 0.0% | 327 | -25.7% | 0.00% | – |
| Q2 2017 | $12,000 | -78.9% | 440 | -73.5% | 0.00% | – |
| Q1 2017 | $57,000 | +18.8% | 1,659 | -5.7% | 0.00% | – |
| Q4 2016 | $48,000 | -91.2% | 1,759 | -89.8% | 0.00% | – |
| Q3 2016 | $547,000 | +138.9% | 17,231 | +144.8% | 0.00% | – |
| Q2 2016 | $229,000 | +61.3% | 7,039 | +38.3% | 0.00% | – |
| Q1 2016 | $142,000 | +153.6% | 5,090 | +226.5% | 0.00% | – |
| Q4 2015 | $56,000 | +107.4% | 1,559 | +92.5% | 0.00% | – |
| Q3 2015 | $27,000 | -44.9% | 810 | -62.5% | 0.00% | – |
| Q2 2014 | $49,000 | +2350.0% | 2,160 | +2060.0% | 0.00% | – |
| Q1 2014 | $2,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |